Back to results
US 2021/0230271 A1Published application
Anti-cd37 antibodies
AssigneeBoehringer Ingelheim International GmbH
InventorsKarl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN
Life of this patent
Estimating the term…
Abstract
Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
Claims4
A nucleic acid molecule encoding an antibody that binds to human CD37, said antibody comprising
- (a) two identical heavy chains, each comprising (i) SEQ ID NO:
- 2, fused to (ii) SEQ ID NO:
- 24 or a mutated form of SEQ ID NO:
- 24, wherein the mutated form has no more than 1, 2 or 3 mutations relative to SEQ ID NO:
- 24 selected from the group consisting of:
- a substitution at position 332, numbered according to the Kabat EU numbering index, wherein the substitution at position 332 is I332E;
- a substitution a position 236, numbered according to the Kabat EU numbering index, wherein the substitution at position 236 is G236A;
- and
- a substitution at position 239, numbered according to the Kabat EU numbering index, wherein the substitution at position 239 is S239D;
- and
- (b) two identical light chains, each comprising SEQ ID NO:
- 4 fused to a human kappa light chain constant region.
9 more elements
A nucleic acid molecule encoding a chimeric antibody that binds to human CD37, wherein the chimeric antibody comprises:
- (a) two identical heavy chains, in which the sequence of each heavy chain is SEQ ID NO:
- 28;
- and
- (b) two identical light chains, in which the sequence of each light chain is SEQ ID NO:
- 30.
2 more elements
Dependencies are inferred from the claim text.